Figure 1. E-cadherin upregulation is prognostic for improved outcomes in sarcoma.
A-B. Osteosarcomas with elevated E-cadherin have better metastasis-free survival (A) and overall survival (B) as compared to tumors with low/no E-cadherin expression. C-D. Soft tissue sarcomas (STS) from The Cancer Genome Atlas with higher E-cadherin mRNA (C) and protein expression (D) have improved overall survival as compared to tumors with low or no E-cadherin.